Multiple Myeloma and Plasma Cell Neoplasm
Oncology
3
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
QT
M&
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Q Therapeuticsmelphalan
Knight Therapeuticsascorbic acid
Merck & Co.bortezomib
Clinical Trials (3)
Total enrollment: 34 patients across 3 trials
High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant
Start: Dec 2007Est. completion: Oct 2013
Phase 2Terminated
Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
Start: Jun 2004Est. completion: Feb 20062 patients
Phase 2Terminated
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
Start: Oct 2008Est. completion: Apr 201532 patients
Phase 1Terminated
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
3m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
3m ago
Office Administrator
SystImmune
4m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
14m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
18m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
18m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space